ClinicalTrials.gg
RecruitingNCT06927739FORTIFYUpdated Jan 27, 2026

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

A Phase 2 interventional study of Orticumab and Placebo in Acute Coronary Syndromes, Coronary Arterial Disease (CAD) and Inflammation, sponsored by Abcentra. Recruiting at 41 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Abcentra · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Acute Coronary Syndrome with a site in United States — 14 open to participants now, 21 under way, 2 of them phase 3. Acute Coronary Syndrome · United States.

Planned enrollment
83rd of 186
240 · median 150
Started
2025
with 3 others
Phase 2
29 of 265
2 open now
Primary completion
2027-02
later than 12 of 20 live
Registered
259th of 265
by date

Among the 265 studies in Acute Coronary Syndrome with a site in United States, this one is the 83rd largest by planned enrollment of the 186 interventional ones that give a count, is one of 4 that started in 2025, is one of 29 in phase 2, reaches primary completion later than 12 of the 20 other live ones, and was the 259th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

14 of the 265 studies in Acute Coronary Syndrome with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Acute Coronary Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:

Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA

Researchers will compare the effects with placebo group after 6 months of treatment

Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Read the detailed description

Participants will have the opportunity to participate in a Day 14 sub study. Participants who enroll in this optional sub study will have safety assessment (AE monitoring) and a blood sample obtained for serum orticumab concentration measurement, ADA titer, clinical safety labs and cardiometabolic and inflammation biomarkers.

03

Conditions studied

  • Acute Coronary Syndromes
  • Coronary Arterial Disease (CAD)
  • Inflammation
  • Heart Disease
  • Myocardial Infarct
  • Atherosclerotic Coronary Vascular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must provide before any study specific activities are performed, must be able and willing to meet all requirements for randomization and must adhere to the schedules of activities.
  2. Participant must be >180 days after presumed type-1 myocardial infarction (i.e., due to plaque rupture or erosion, either STEMI or NSTEMI) without subsequent unstable or severe angina (Canadian Cardiovascular Society Class 3 or 4) at the time of enrollment. Participants who have undergone PCI are allowed.
  3. Participant must be on a stable cardiovascular treatment regimen consistent with local treatment guidelines for post-AMI patients (such as maximally tolerated statin and/or PCSK9 inhibitor medication for LDL reduction, antiplatelet medication, and hypertension treatment).
  4. Participant must have an evaluable, pre-randomization CCTA with one of the following:

    1. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 50th centile (per reference standard) for their age group in at least two coronary arteries or
    2. A quantifiable Fat Attenuation Index (FAI) Score greater than or equal to the 75th centile (per reference standard) for their age group in at least one coronary artery
  5. Participant must have (BMI) ≤ 40 kg/m2.
  6. Adult male and female participants ≥18 years of age at the Screening Visit:

For female participants, the participant must not be pregnant or lactating and must be one of the following:

  1. , defined as amenorrhea for ≥ 12 months following cessation of all exogenous hormonal treatments; follicle stimulating hormone levels may be obtained at the investigator's discretion to confirm the participant is postmenopausal.
  2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical sterilization.
  3. Females of must have a negative serum or urine pregnancy test prior to the start of study drug. In the case of positive urine pregnancy testing, a negative serum sample for pregnancy testing, to confirm that the participant is not pregnant, must be obtained prior to start of study. They must also agree to use an adequate method of from Baseline through the End of the study or for 30 days after the last dose of study drug (whichever is longer), which include the following: sexual abstinence (if preferred and usual lifestyle of the participant), condom with spermicidal gel, diaphragm with spermicidal gel, coil (intrauterine device), surgical sterilization, vasectomy, oral contraceptive pill, depo progesterone injections, progesterone implant (i.e., Implanon®), NuvaRing®, Ortho Evra®.

For male participants - Nonsterile male participants with sexual partners of childbearing potential must agree to use an adequate method of contraception, including sexual abstinence (if preferred and usual lifestyle of the participant), from Baseline through the End of the study.

Exclusion criteria

Exclusion Criteria:

  1. History of any disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  2. Percutaneous coronary intervention or invasive diagnostic coronary angiogram planned after screening. Eligible participants who have an invasive diagnostic coronary angiogram performed in the absence of undergoing a new PCI may continue screening after the diagnostic angiogram has been performed or may be rescreened.
  3. History of or planned coronary artery bypass grafting.
  4. Documented episode of post-MI pericarditis in the 3 months before enrollment.
  5. Presence of unstable or uncontrolled angina. Canadian CV society (CCS) angina class > 2.
  6. Ongoing Class IV HF.
  7. Poorly controlled type 1 or type 2 diabetes mellitus ( >8.0%).
  8. Increased risk of bleeding:

    1. With history or presence of any bleeding disorder.
    2. Signs of ongoing bleeding at screening (e.g., identified macroscopic bleeding, low presumed to be caused by bleeding) or high risk for major bleeding in accordance with the Investigator's assessment (participants taking clinically indicated antiplatelet and antithrombotic agents are acceptable).
    3. Known severe liver disease (e.g., >5´ elevations in and/or AST and other evidence of grade 3 or higher criteria applies such as from the 5.0 guidelines).
  9. History or presence of any of the following:

    1. Ongoing infection or febrile illness.
    2. Ongoing persistent or permanent atrial fibrillation or flutter.
    3. Cancer within 5 years before randomization, with the exception of non-melanoma skin cancer.
    4. Alcohol or substance abuse within 6 months before randomization, as judged by the investigator.
    5. Known history of reactions to other biologics, to human IgG preparations, or to any component of orticumab, or ongoing severe allergy as judged by the investigator.
    6. Active positive results on screening for serum core antibody.
    7. Clinically documented or .
  10. Any clinically important abnormalities in clinical chemistry, hematology, coagulation parameters, as judged by the investigator.
  11. Blood pressure values at screening (taken as the average of triplicate measurements):

    1. Systolic blood pressure \< 90 mmHg or > 180 mmHg.
    2. Diastolic blood pressure > 100 mmHg.
    3. One triplicate retest (repeat of all 3) will be allowed during the same visit, at which point if the retest result is no longer exclusionary, the participant may be randomized
    4. Participants who are excluded based on elevated blood pressure may be rescreened following adequate treatment.
  12. Participants with any of the following to CCTA.

    1. \< 40 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration equation, or end stage renal disease treated with kidney transplant or renal replacement therapy.
    2. Allergy to iodinated contrast.
    3. History of contrast-induced nephropathy.
    4. Contraindication to nitroglycerin.
    5. Rapid heart rate that is uncontrolled by medical therapy.
    6. Inability to hold breath for at least 6 seconds.
  13. Use of any of the following in the 180 days before randomization: IL-17 inhibitor, TNF inhibitor, IL-6 inhibitor, IL-1β inhibitor, methotrexate, cyclosporine, apremilast, colchicine, systemic (topical steroid use is allowed).
  14. COVID-19 vaccine within 90 days of screening CCTA.
  15. Participants with a confirmed positive COVID-19 test within 90 days of screening CCTA.
  16. Receipt of any device or therapy within 6 months or 5 half-lives before screening (whichever is longer).
  17. Planned participation in an additional investigational study of an intervention or biologic before the end of the follow-up period. Participation in observational studies or studies without investigational drugs or devices is allowed.
  18. Participants who have previously been exposed to orticumab.
  19. Participants who are legally institutionalized.
  20. An employee or close relative of an employee of the sponsor, the CRO, or the study site, regardless of the employee or close relative's role.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Orticumab High Dose

    Drug: Orticumab

  • Active comparator
    Orticumab Low Dose

    Drug: Orticumab

  • Placebo comparator
    Placebo High Dose

    Drug: Placebo

  • Placebo comparator
    Placebo Low Dose

    Drug: Placebo

Interventions

  • Orticumab treatment for 24 weeks for post MI population

    Also known as: MLDL1278a, BI204

  • DrugPlacebo

    Placebo for 24 weeks for the post MI population

06

What researchers measure

Primary outcomes

  1. Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeks

    Analysis of the mean FAI score around the coronary arteries will be performed from baseline and 6-month Coronary Computed Tomography Angiography (CCTA) procedures. FAI-score is a standardized measurement of coronary inflammation for each coronary artery (adjusted for age, sex as well as technical, biological, and anatomical characteristics) to allow individualized interpretation of the degree of coronary inflammation. FAI-Score is given at a scale of 0-100 with arbitrary unit. A higher FAI-score indicates an increase coronary inflammation.

    Time frame: 24 weeks

Secondary outcomes

  1. Change from baseline for coronary artery inflammation

    Change from baseline for Fat Attenuation Index (FAI) parameters for orticumab compared to placebo after 24 weeks of treatment assessed by Coronary Computed Tomography Angiography (CCTA)

    Time frame: 24 weeks

  2. Change from baseline for CaRi-Heart score for orticumab compared to placebo at 24 weeks of treatment

    CaRi-Heart Risk score represents the individualized patient risk of a fatal cardiac event at 8 years which incorporates the FAI score values into a prognostic model that includes information about CCTA-derived plaque metrics and clinical cardiovascular risk factors (diabetes, smoking, hypertension, hyperlipidemia).

    Time frame: 24 weeks

Other outcomes

  1. Change in coronary artery plaque burden accessed by Coronary Computed Tomography Angiography (CCTA) at 24 weeks

    Change in coronary artery plaque parameters for orticumab compared to placebo at 24 weeks of treatment assessed by CCTA

    Time frame: 24 weeks

  2. Change in radiotranscriptomic biomarkers of coronary inflammation as assessed by Coronary Computed Tomography Angiography (CCTA)

    Change from baseline on radiotranscriptomic biomarkers of coronary inflammation (e.g. C19RS) as measured by CCTA compared to placebo to determine the effects of orticumab treatment on coronary inflammation

    Time frame: 24 weeks

  3. Number and percent of participants with treatment-emergent adverse events (TEAEs), and any serious adverse events

    Time frame: 24 weeks

  4. Incident of abnormal vital signs

    Vital signs (including blood pressure and pulse rate) are measured and recorded at every visit to assess the safety and tolerability of orticumab in study participants. Incidence of abnormal vital signs will be recorded.

    Time frame: 24 weeks

  5. Number of participants with abnormal laboratory tests results and abnormal physical exam findings

    Time frame: 24 weeks

07

Study locations

39 of 41 sites recruiting
  • Abcentra Investigational Site
    Los Angeles, California 90048, United States
    Not yet recruiting
  • Abcentra Investigational Site
    Torrance, California 90502, United States
    Recruiting
  • Abcentra Investigational Site
    Boca Raton, Florida 33434, United States
    Recruiting
  • Abcentra Investigational Site
    Richmond, Indiana 47374, United States
    Recruiting
  • Abcentra Investigational Site
    Louisville, Kentucky 40202, United States
    Not yet recruiting
  • Abcentra Investigational Site
    Baltimore, Maryland 21215, United States
    Recruiting
  • Abcentra Investigational Site
    Midland, Michigan 48670, United States
    Recruiting
  • Abcentra Investigational Site
    Ostrava, Moravian-Silesian Region 728 80, Czechia
    Recruiting
  • Abcentra Investigational Site
    Pilsen, Plzeň Region 323 00, Czechia
    Recruiting
  • Abcentra Investigational Site
    Prague, Praha 2 128 08, Czechia
    Recruiting
  • Abcentra Investigational Site
    Prague, Praha 4 140 21, Czechia
    Recruiting
  • Abcentra Investigational Site
    Brno, South Moravian 602 00, Czechia
    Recruiting
  • Abcentra Investigational Site
    Pécs, Baranya 7635, Hungary
    Recruiting
  • Abcentra Investigational Site
    Budapest, Central Hungary 1036, Hungary
    Recruiting
  • Abcentra Investigational Site
    Budapest, Central Hungary 1094, Hungary
    Recruiting
  • Abcentra Investigational Site
    Budapest, Central Hungary 1132, Hungary
    Recruiting
  • Abcentra Investigational Site
    Nyíregyháza, Szabolcs-Szatmár-Bereg 4400, Hungary
    Recruiting
  • Abcentra Investigational Site
    Caserta, Campania 81100, Italy
    Recruiting
  • Abcentra Investigational Site
    Ferrara, Ferrara 44124, Italy
    Recruiting
  • Abcentra Investigational Site
    Brescia, Lombardy 25123, Italy
    Recruiting
  • Abcentra Investigational Site
    Milan, Lombardy 20162, Italy
    Recruiting
  • Abcentra Investigational Site
    Pavia, Lombardy 27100, Italy
    Recruiting
  • Abcentra Investigational Site
    Krakow, Lesser Poland Voivodeship 30-082, Poland
    Recruiting
  • Abcentra Investigational Site
    Wroclaw, Lower Silesian Voivodeship 50-556, Poland
    Recruiting
  • Abcentra Investigational Site
    Warsaw, Masovian Voivodeship 03-505, Poland
    Recruiting
  • Abcentra Investigational Site
    Baia Mare, Maramureş 430031, Romania
    Recruiting
  • Abcentra Investigational Site
    Târgu Mureş, Mureș County 540124, Romania
    Recruiting
  • Abcentra Investigational Site
    Timișoara, Timiș County 300060, Romania
    Recruiting
  • Abcentra Investigational Site
    Córdoba, Andalusia 14004, Spain
    Recruiting
  • Abcentra Investigational Site
    Madrid, Madrid 28034, Spain
    Recruiting
  • Abcentra Investigational Site
    Madrid, Madrid 28046, Spain
    Recruiting
  • Abcentra Investigational Site
    El Palmar, Murcia 30120, Spain
    Recruiting
  • Abcentra Investigational Site
    Seville, Sevilla 41009, Spain
    Recruiting
  • Abcentra Investigational Site
    Danderyd, Stockholm County 182 88, Sweden
    Recruiting
  • Abcentra Investigational Site
    Solna, Stockholm County 171 76, Sweden
    Recruiting
  • Abcentra Investigational Site
    Gothenburg, Västra Götaland County 413 45, Sweden
    Recruiting
  • Abcentra Investigational Site
    London, Greater London EC1M 6BQ, United Kingdom
    Recruiting
  • Abcentra Investigational Site
    Manchester, Greater Manchester M23 9LT, United Kingdom
    Recruiting
  • Abcentra Investigational Site
    Oxford, Oxfordshire OX3 9DU, United Kingdom
    Recruiting
  • Abcentra Investigational Site
    Bath, Somerset BA1 3NG, United Kingdom
    Recruiting
  • Abcentra Investigational Site
    Sheffield, South Yorkshire S57AU, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

Of 30 phase 2 interventional studies under Acute Coronary Syndrome, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 15, 2025
StartActual
Aug 11, 2025
Primary completionEst.
Feb 8, 2027
CompletionEst.
Jun 1, 2027
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06927739
Lead sponsor
Abcentra
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Aug 11, 2025
Primary completion
Feb 8, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Jan 27, 2026

Study contacts

Abcentra
Contact
info@abcentra.com
424-369-4401

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLDL1278A

Start the discussion